2023-04-25 09:02:39 ET
- The US FDA has granted Orphan Drug designation to IN8bio's ( NASDAQ: INAB ) INB-400 and INB-410 to treat several types of glioma.
- Both are gamma-delta T cell therapies intended to initially treat glioblastoma multiform, a type of brain cancer.
- Patient enrollment in a phase 2 trial for INB-400 is set to begin in the second half of the year .
- Despite the positive news, IN8bio shares are down 10% in premarket trading Tuesday.
- On Monday, IN8bio ( INAB ) rose more than 100% on data from a phase 1 trial of INB-100 in patients with leukemia
For further details see:
IN8bio wins FDA Orphan Drug designation for glioma candidates